25 May 2013
Keywords: Menarini, Oxford BioTherapeutics, Antibody-based cancver drugs
Article | 29 October 2012
In a second major deal within just over a year for the UK-based antibody-based drug developer, BioTherapeutics (OBT) has entered ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 October 2012
24 May 2013
© 2013 thepharmaletter.com